| All Patients | Adalimumab | Etanercept | |
| N | 550 | 166 | 384 |
| Females | 68% | 59% | 71% |
| Age (years), median (IQR) | 12 (8-14) | 12 (10-14) | 11 (8-14) |
| Disease duration (years), median (IQR) | 1 (1-4) | 1 (0-3) | 1 (1-4) |
| ILAR | |||
| Persistent oligo | 9% | 6% | 11% |
| Extended oligo | 20% | 14% | 23% |
| RF negative | 37% | 32% | 39% |
| RF positive | 11% | 11% | 12% |
| Psoriatic | 5% | 8% | 4% |
| Enthesitis-related | 16% | 27% | 11% |
| Undifferentiated | 1% | 2% | 1% |
| Concomitant oral steroids | 16% | 20% | 15% |
| Concomitant methotrexate | 72% | 84% | 66% |
| Follow-up time, years | |||
| Median (IQR) | 2.5 (1.4-3.8) | 2.1 (1.2-3.1) | 3.0 (1.6-4.0) |
| Min-Max | 0.4 - 8.2 | 0.4 - 7.3 | 0.4 - 8.2 |
| Drug Survival | |||
| Still on drug at one year | 70% | 67% | 71% |
| Still on drug at two years | 47% | 50% | 46% |
| CHAQ | |||
| Baseline, mean (SE) | 0.9 (0.04) | 0.8 (0.06) | 1.0 (0.04) |
| One Year, mean (SE) | 0.7 (0.03) | 0.5 (0.06) | 0.7 (0.04) |
| Change, mean (SE) | -0.2 (0.04) | -0.2 (0.06) | -0.2 (0.04) |
| Regression coef (95% CI) | - | -0.09 (-0.2, 0.04) | Ref |
| PD Adjusted coef (95% CI) | - | -0.08 (-0.2, 0.07) | Ref |
| MCID (CHAQ) | |||
| Proportion achieved | 48% | 48% | 48% |
| OR (95% CI) | - | 1.0 (0.6, 1.5) | Ref |
| PD Adjusted OR (95% CI) | - | 1.2 (0.8, 1.9) | Ref |
| JADAS | |||
| Baseline, mean (SE) | 14 (0.4) | 14 (0.7) | 14 (0.4) |
| One Year, mean (SE) | 5 (0.3) | 4 (0.5) | 6 (0.3) |
| Change, mean (SE) | -9 (0.4) | -9 (0.7) | -8 (0.5) |
| Regression coef (95% CI) | - | -1.1 (-2.3, -0.01)* | Ref |
| PD Adjusted coef (95% CI) | - | -1.0 (-2.8, 0.8) | Ref |
| Inactive Disease (JADAS<1) | |||
| Proportion achieved | 26% | 32% | 24% |
| OR (95% CI) | - | 1.5 (1.0, 2.4) | Ref |
| PD Adjusted OR (95% CI) | - | 1.5 (0.9, 2.4) | Ref |
| Minimal Disease Activity (MDA) [excludes enthesitis-related JIA] | N=473 | N=121 | N=352 |
| Proportion achieved | 46% | 49% | 45% |
| OR (95% CI) | - | 1.2 (0.8, 1.9) | Ref |
| PD Adjusted OR (95% CI) | - | 1.2 (0.8, 2.0) | Ref |
Childhood Health Assessment Questionnaire (CHAQ), confidence interval (CI), International League Against Rheumatism (ILAR), interquartile range (IQR), odds ratio (OR), propensity decile (PD), rheumatoid factor (RF), standard error (SE). *p<0.05